The immunology of sepsis

Journal of Pathology

Volumn 214, Issue 2, 2008, Pages 211-223

  Sriskandan, S ^a   Altmann, D M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Gene polymorphism; Group A steptococci; Sepsis; Superantigen

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6;

ADAPTIVE IMMUNITY; APOPTOSIS; BLOOD CLOTTING; CYTOKINE PRODUCTION; DNA POLYMORPHISM; ENDOTHELIAL DYSFUNCTION; GENETIC POLYMORPHISM; HUMAN; IMMUNOGENETICS; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SEX DIFFERENCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACUTE-PHASE REACTION; ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; SEPSIS; SUPERANTIGENS;

EID: 38549180598     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2274     Document Type: Review

References (105)

1. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al., Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344-353.
2. Bone R, Balk RA, Cerra FB, Dellinger RR, Fein AM, Knaus WA and the ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655.
3. Thomas L. Germs. N Engl J Med 1972;287:553-555.
4. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002;2:156-162.
5. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150.
6. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007;170:1435-1444.
7. Hopkins PA, Fraser JD, Pridmore AC, Russell HH, Read RC, Sriskandan S. Superantigen recognition by HLA class II on monocytes up-regulates toll-like receptor 4 and enhances proinflammatory responses to endotoxin. Blood 2005;105:3655-3662.
8. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004;21:733-741.
9. Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006;116:485-494.
10. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002;8:1398-1404.
11. Llewelyn M, Sriskandan S, Peakman M, Ambrozak DR, Douek DC, Kwok WW, et al. HLA class II polymorphisms determine responses to bacterial superantigens. J Immunol 2004;172:1719-1726.
12. Nooh M, El-Gengehi N, Kansal R, David CS, Kotb M. HLA transgenic mice provide evidence for a direct and dominant role of HLA class II variation in modulating the severity of streptococcal sepsis. J Immunol 2007;178:3076-3083.
13. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3:710-720.
14. Selsted ME, Ouell AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005;6:551-557.
15. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004;75:39-48.
16. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol 2004;41:1089-1098.
17. Yuste J, Ali S, Sriskandan S, Hyams C, Botto M, Brown JS. Roles of the alternative complement pathway and C1q during innate immunity to Streptococcus pyogenes. J Immunol 2006;176:6112-6120.
18. Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin - a soluble pattern recognition molecule. Mol Immunol 2004;41:113-121.
19. Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J. A critical role of natural immunoglobulin M in immediate defence against systemic bacterial infection. J Exp Med 1998;188:2381-2386.
20. Bochud PY, Calandra T, Francioli P. Bacteraemia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256-264.
21. Kinane DF, Riggio MP, Walker KF, MacKenzie D, Shearer B. Bacteraemia following periodontal procedures. J Clin Periodontal 2005;32:708- 713.
22. Carlsson F, Berggard K, Stalhammar-Carlemalm M, Lindahl G. Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein. J Exp Med 2003;198:1057- 1068.
23. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169:10-14.
24. Inohara C, McDonald C, Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005;74:355-383.
25. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
26. Kawai T, Akira S. TLR signalling. Semin Immunol 2007;19:24-32.
27. Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster SK, Cartwright N. Critical role of toll-like receptors and nucleotide oligomerization domain in the regulation of health and disease. J Endocrinol 2007;193:323- 330.
28. Hopkins PA, Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol 2005;140:395-407.
29. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, et al. CD36 is a sensor of diacylglycerides. Nature 2005;433:523-527.
30. Cartwright N, McMaster SK, Sorrentino R, Paul-Clark M, Sriskandan S, Ryffel B, et al. Elucidation of toll-like receptor and adapter protein signalling in vascular dysfunction induced by Gram-positive Staphylococcus aureus or Gram-negative Escherichia coli. Shock 2007;27:40-47.
31. Jimenez R, Belcher E, Sriskandan S, Lucas R, McMaster S, Vojnovic I, et al. Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc Natl Acad Sci USA 2005;102:4637-4642.
32. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004;5:975-979.
33. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players rules and the games. Immunology 2005;115:1-20.
34. Faulkner L, Altmann DM, Ellmerich S, Huhtaniemi I, Stamp G, Sriskandan S. Sexual dimorphism in superantigen shock involves elevated TNFα and TNFα-induced hepatic apoptosis. Am J Resp Crit Care Med 2007;176:473-482.
35. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-689.
36. Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis 2005;192:783-790.
37. Bestebroer J, Poppelier MJ, Ulfman LH, Lenting PJ, Denis CV, van Kessel KP, et al. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 2007;109:2936-2943.
38. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3:791-800.
39. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001;414:920-924.
40. Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007;21:1267-1280.
41. Sprong T, Pickkers P, Geurts-Moespot A, van der Ven-Jongekrijg J, Neeleman C, Knaup M, et al. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxaemia. Shock 2007;27:482-487.
42. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006;26:174-179.
43. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203:1637-1642.
44. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997;181:257-266.
45. Noursadeghi M, Bickerstaff MC, Herbert J, Moyes D, Cohen J, Pepys MB. Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. J Immunol 2002;169:913-919.
46. Noursadeghi M, Pepys MB, Gallimore R, Cohen J. Relationship of granulocyte colony stimulating factor with other acute phase reactants in man Clin Exp Immunol 2005;140:97-100.
47. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 2004;116:367-379.
48. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997;3:678-681.
49. Goldmann O, Rohde M, Chhatwal GS, Medina E. Role of macrophages in host resistance to group A streptococci. Infect Immun 2004;72:2956- 2963.
50. Goldmann O, von Kockritz-Blickwede M, Holtje C, Chhatwal GS, Geffers R, Medina E. Transcriptome analysis of murine macrophages in response to infection with Streptococcus pyogenes reveals an unusual activation program. Infect Immun 2007;75:4148-4157.
51. Tracey KJ. The inflammatory reflex. Nature 2002;420:853- 859.
52. Sriskandan S, Moyes D, Buttery LK, Krausz T, Evans TJ, Polak J, et al. Streptococcal pyrogenic exotoxin A release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes. J Infect Dis 1996;173:1399-1407.
53. Wayte J, Silva AT, Krausz T, Cohen J. Observations on the role of tumor necrosis factor-alpha in a murine model of shock due to Streptococcus pyogenes. Crit Care Med 1993;21:1207-1212.
54. Faulkner L, Cooper A, Fantino C, Altmann DM, Sriskandan S. The mechanism of superantigen-mediated toxic shock: not a simple cytokine storm. J Immunol 2005;175:6870-6877.
55. Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA, et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxaemia and polymicrobial sepsis. J Exp Med 2006;203:1623-1628.
56. Beutler B, Grau GE. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993;21(10 suppl):S423-435.
57. Pruitt JH, Copeland EM III. Moldawer LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock 1995;3:235-251.
58. Kengatharan KM, De Kimpe SJ, Thiemermann C. Role of nitric oxide in the circulatory failure and organ injury in a rodent model of Gram-positive shock. Br J Pharmacol 1996;119:1411-1421.
59. Evans T, Carpenter A, Silva A, Cohen J. Inhibition of nitric oxide synthase in experimental Gram-negative sepsis. J Infect Dis 1994;169:343-349.
60. Sriskandan S, Moyes D, Buttery LK, Wilkinson J, Evans TJ, Polak J, et al. The role of nitric oxide in experimental murine sepsis due to pyrogenic exotoxin A-producing Streptococcus pyogenes. Infect Immun 1997;65:1767-1772.
61. López A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30.
62. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001;29:S121-125.
63. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004;363:203-209.
64. Hotchkiss RS, Nicholson DW. Apotosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006;6:813-822.
65. Chang KC, Unsinger J, Davis CG, Schwulst SJ, Muenzer JT, Strasser A, et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial mediated apoptosis. FASEB J 2007;21:708-719.
66. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-1251.
67. Sriskandan S, Unnikrishnan M, Krausz T, Dewchand H, Van Noorden S, Cohen J, et al. Enhanced susceptibility to super-antigen-associated streptococcal sepsis in human leukocyte antigen-DQ transgenic mice. J Infect Dis 2001;184:166-173.
68. De Freitas I, Fernandez-Somoza M, Essenfeld-Sekler E, Cardier JE. Serum levels of the apoptosis-associated molecules, tumor necrosis factor-alpha/tumor necrosis factor type-I receptor and Fas/FasL, in sepsis. Chest 2004;125:2238-2246.
69. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 2000;403:98-103.
70. Saleh M, Mathison JC, Wolinski MK, Bensinger SJ, Fitzgerald P, Droin N, et al. Enhanced bacterial clearance and sepsis resistance in caspase- 12-deficient mice. Nature 440:1064-1068.
71. Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasa SM, Alnemri ES, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004;429:75-79.
72. Tracey KJ, Warren HS. Human genetics: an inflammatory issue. Nature 2004;429:35-37.
73. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005;15:254-259.
74. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intens Care Med 2004;30:1032-1040.
75. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-3777.
76. Frick IM, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007;98:497-502.
77. Hill AV. Aspects of genetic susceptibility to human infectious diseases. Annu Rev Genet 2006;40:469-486.
78. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 2006;84:370-378.
79. + regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J Immunol 2005;175:5591-5595.
80. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. J Am Med Assoc 1999;282:561-568.
81. Arcarolli J, Fessier MB, Abraham E. Genetic polymorphisms and sepsis. Shock 2005;24:300-312.
82. Gordon AC, Lagan AL, Aganna E, Cheung L, Peters CJ, McDermott MF, et al. TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immun 2004;5:631-640.
83. Read RC, Cannings C, Naylor SC, Timms JM, Maheswaran R, Borrow R, et al. Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003;138:534-541.
84. Papathanassoglou E, Giannakopolou M, Bozes E. Genomic variation in susceptibility to sepsis. AACN Adv Crit Care 2006;17:394-422.
85. Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 2005;33:89-97.
86. Sutherland AM, Walley KR, Manocha S, Russell JA. The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch Int Med 2005;165:75-82.
87. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003;31:34-38.
88. Proft T, Fraser JD. Bacterial superantigens. Clin Exp Immunol 2003;133:299-306.
89. Raj HD, Bergdoll MS. Effect of enterotoxin B on human volunteers. J Bacteriol 1969;98:833-834.
90. Herman A, Kappler JW, Marrack P, Pullen AM. Superantigens: mechanism of T-cell stimulation and role in immune responses. Ann Rev Immunol 1991;9:745-772.
91. Unnikrishnan M, Altmann DM, Proft T, Wahid F, Cohen J, Fraser D, et al. The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes. J Immunol 2002;169:2561-2569.
92. Llewelyn M, Sriskandan S, Terrazzini N, Cohen J, Altmann DM. The TCR Vb signature of bacterial superantigens spreads with stimulus strength. Int Immunol 2006;18:1433-1441.
93. Choi Y, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, et al. Selective expansion of T cells expressing Vb2 in toxic shock syndrome. J Exp Med 1990;172:981-984.
94. Marrack P, Blackman P, Kusnir E, Kappler J. The toxicity of staphylococcal enterotoxin B is mediated by T cells. J Exp Med 1990;171:455-464.
95. Sriskandan S, Moyes D, Cohen J. Detection of circulating bacterial superantigen and lymphotoxin-a in patients with streptococcal toxic shock syndrome. Lancet 1996;348:1315-1316.
96. Proft T, Sriskandan S, Yang L, Fraser JD. Superantigens and streptococcal toxic shock syndrome. Emerg Inf Dis 2003;9:1211-1218.
97. Yang L, Thomas M, Woodhouse A, Martin D, Fraser JD, Proft T. Involvement of streptococcal mitogenic exotoxin Z in streptococcal toxic shock syndrome. J Clin Microbiol 2005;43:3570-3573.
98. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007;146:193-203.
99. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511.
100. Guilherme L, Oshiro SE, Fae KC, Cunha-Neto E, Renesto G, Goldberg AC, et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001;69:5345-5351.
101. Fae KC, da Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, Douay C, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 2006;176:5662-5670.
102. Thulin P, Johansson L, Low DE, Gan BS, Kotb M, McGeer A, et al. Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med 2006;3(3):e53.
103. + regulatory ∼T cells increases bacterial clearance and improves survival in polymicrobial sepsis. J Immunol 2005;174:7141-7146.
104. + regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol 2006;177:7943-7949.
105. - lymphocytes. Crit Care Med 2004;32:2329-2331.